138 related articles for article (PubMed ID: 37909437)
1. Biological Significance of EphB4 Expression in Cancer.
Ullah A; Razzaq A; Zhou C; Ullah N; Shehzadi S; Aziz T; Alfaifi MY; Elbehairi SEI; Iqbal H
Curr Protein Pept Sci; 2024; 25(3):244-255. PubMed ID: 37909437
[TBL] [Abstract][Full Text] [Related]
2. Targeting receptor tyrosine kinase EphB4 in cancer therapy.
Chen Y; Zhang H; Zhang Y
Semin Cancer Biol; 2019 Jun; 56():37-46. PubMed ID: 28993206
[TBL] [Abstract][Full Text] [Related]
3. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.
Noren NK; Yang NY; Silldorff M; Mutyala R; Pasquale EB
Biochem J; 2009 Aug; 422(3):433-42. PubMed ID: 19552627
[TBL] [Abstract][Full Text] [Related]
4. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia.
Kuang SQ; Bai H; Fang ZH; Lopez G; Yang H; Tong W; Wang ZZ; Garcia-Manero G
Blood; 2010 Mar; 115(12):2412-9. PubMed ID: 20061560
[TBL] [Abstract][Full Text] [Related]
5. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4.
Duggineni S; Mitra S; Noberini R; Han X; Lin N; Xu Y; Tian W; An J; Pasquale EB; Huang Z
Biochem Pharmacol; 2013 Feb; 85(4):507-13. PubMed ID: 23253822
[TBL] [Abstract][Full Text] [Related]
7. Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers.
Liersch-Löhn B; Slavova N; Buhr HJ; Bennani-Baiti IM
Int J Cancer; 2016 Mar; 138(5):1220-31. PubMed ID: 26414866
[TBL] [Abstract][Full Text] [Related]
8. EphrinB2-EphB4 Signaling in Neurooncological Disease.
Piffko A; Uhl C; Vajkoczy P; Czabanka M; Broggini T
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163601
[TBL] [Abstract][Full Text] [Related]
9. Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers.
Alam SM; Fujimoto J; Jahan I; Sato E; Tamaya T
Gynecol Oncol; 2009 Jul; 114(1):84-8. PubMed ID: 19356789
[TBL] [Abstract][Full Text] [Related]
10. Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
Piffko A; Broggini T; Harms C; Adams RH; Vajkoczy P; Czabanka M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360793
[TBL] [Abstract][Full Text] [Related]
11. Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer.
Takai N; Miyazaki T; Fujisawa K; Nasu K; Miyakawa I
Oncol Rep; 2001; 8(3):567-73. PubMed ID: 11295082
[TBL] [Abstract][Full Text] [Related]
12. Expression of Ephb2 and Ephb4 in breast carcinoma.
Wu Q; Suo Z; Risberg B; Karlsson MG; Villman K; Nesland JM
Pathol Oncol Res; 2004; 10(1):26-33. PubMed ID: 15029258
[TBL] [Abstract][Full Text] [Related]
13. Distribution of EphB4 and EphrinB2 in normal and malignant urogenital tissue.
Ozgür E; Heidenreich A; Dagtekin O; Engelmann U; Bloch W
Urol Oncol; 2011; 29(1):78-84. PubMed ID: 19272799
[TBL] [Abstract][Full Text] [Related]
14. Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy.
Zamora DO; Davies MH; Planck SR; Rosenbaum JT; Powers MR
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2175-82. PubMed ID: 15914639
[TBL] [Abstract][Full Text] [Related]
15. EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target.
Xiao Z; Carrasco R; Kinneer K; Sabol D; Jallal B; Coats S; Tice DA
Cancer Biol Ther; 2012 Jun; 13(8):630-7. PubMed ID: 22555806
[TBL] [Abstract][Full Text] [Related]
16. Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts.
Kwan Tat S; Pelletier JP; Amiable N; Boileau C; Lajeunesse D; Duval N; Martel-Pelletier J
Arthritis Rheum; 2008 Dec; 58(12):3820-30. PubMed ID: 19035475
[TBL] [Abstract][Full Text] [Related]
17. A narrative review of the role of Eph receptors in head and neck squamous cell carcinoma.
Al-Jamaei AAH; Subramanyam RV; Helder MN; Forouzanfar T; van der Meij EH; Al-Jamei S; de Visscher JGAM
Oral Dis; 2024 Apr; 30(3):833-845. PubMed ID: 37279081
[TBL] [Abstract][Full Text] [Related]
18. EphrinB2 and EphB4 expression in pterygia: new insights and preliminary results.
Xue C; Huang Z; Wang J; Dong Y; Zhou X
Can J Ophthalmol; 2009 Apr; 44(2):185-8. PubMed ID: 19491953
[TBL] [Abstract][Full Text] [Related]
19. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of eph receptor kinase activation in cancer cells by coexpressed ephrin ligands.
Falivelli G; Lisabeth EM; Rubio de la Torre E; Perez-Tenorio G; Tosato G; Salvucci O; Pasquale EB
PLoS One; 2013; 8(11):e81445. PubMed ID: 24348920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
